Last reviewed · How we verify
Vikasolum (MENADIONE SODIUM BISULFITE)
Vikasolum (generic name: MENADIONE SODIUM BISULFITE) is a drug. It is currently in Phase 2 development.
Vikasolum works by interacting with and stabilizing vitamin K-dependent proteins in the body.
Vikasolum, also known as Menadione Sodium Bisulfite, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological pathways, but the exact mechanism is unknown. Further research is needed to understand its potential therapeutic applications and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MENADIONE SODIUM BISULFITE |
|---|---|
| Target | Aldose reductase |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
Think of vitamin K-dependent proteins like the locks on a door. Vikasolum helps keep these locks stable, allowing them to function properly. This is important because these proteins play a crucial role in blood clotting and other bodily processes.
Approved indications
Common side effects
Key clinical trials
- Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (NA)
- Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vikasolum CI brief — competitive landscape report
- Vikasolum updates RSS · CI watch RSS
Frequently asked questions about Vikasolum
What is Vikasolum?
How does Vikasolum work?
What is the generic name of Vikasolum?
What development phase is Vikasolum in?
What does Vikasolum target?
Related
- Target: All drugs targeting Aldose reductase
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing